News

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...
Not letting its expansion efforts idle, contract manufacturer PCI Pharma Services is picking up a 100% stake in Ajinomoto's ...
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...
After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...